您好，欢迎来到试剂仪器网！ [登录] [免费注册]
试剂仪器网
发布求购
位置：首页 > 产品库 > MLN3126
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
MLN3126
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
MLN3126图片
CAS NO:628300-71-0
包装与价格：
包装价格(元)
10mg电议
25mg电议
50mg电议

产品介绍
MLN3126 是一种具有口服活性的强效 CCR9 拮抗剂。 MLN3126 抑制 CCL25 诱导的钙动员 (calcium mobilization) 和小鼠初级胸腺细胞趋化 (chemotaxis)，抑制钙内流的 IC50 为 6.3 nM。
Cas No.628300-71-0
分子式C21H19ClN2O5S
分子量446.9
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

MLN3126 is an orally active and potentCCR9antagonist. MLN3126 inhibits CCL25-induced calcium mobilization and chemotaxis of mouse primary thymocytes, wiht anIC50value of 6.3 nM forcalcium influx[1].

MLN3126 inhibits CCL25-induced calcium mobilization with an IC50value of 6.3 nM in CCR9 expressing cells[1].
MLN3126 inhibits the binding of biotinylated CCL25 to CCR9 with an IC50of 14.2 nM[1].

Cell Invasion Assay[1]

Cell Line:Mouse thymocytes
Concentration:0.01, 0.03, 0.1, 0.3, 1, 3 μM
Incubation Time:90 min
Result:Inhibited CCL25-induced chemotaxis of mouse thymocytes.

MLN3126 (2.5% w/w; p.o.) decreases colonic level of IFN-γ, largely produced by T cells[1].
MLN3126 (0.05, 0.25 and 1% (w/w); p.o.) has the potential activity for alleviating inflammatory bowel disease (IBD)[1].

Animal Model:Activated T cell transferred colitis mouse model[1]
Dosage:0.05, 0.25 and 1% (w/w) (around 4 g/day)
Administration:Oral gavage; 21 days
Result:Blocked CCR9/CCL25 interaction by inhibiting migration of T cells to the colon and resulted in the amelioration of colitis.